<DOC>
	<DOCNO>NCT01186484</DOCNO>
	<brief_summary>The purpose study ass pharmacodynamics safety JNJ-212082 order select recommend dose JNJ-212082 patient castration resistant prostate cancer .</brief_summary>
	<brief_title>Phase 1 Study Abiraterone Acetate Castration-resistant Prostate Cancer</brief_title>
	<detailed_description>This study multicenter ( one site ) , open-label ( physician patient know name study drug ) , dose-escalation study chemotherapy-naive patient castration- resistant prostate cancer ( CRPC ) evaluate pharmacodynamics ( study action effect drug live organism ) , safety , pharmacokinetics ( drug absorb body , distribute within body remove body time ) preliminary effectiveness JNJ-212082 . The dose study escalate 250 mg ( cohort 1 ) , 500 mg ( cohort 2 ) , 1000 mg ( cohort 3 ) . Six twelve patient within 250 mg , 500 mg 1000 mg cohort orally administer drug per day . Comprising 28 day 1 cycle , administration continue discontinuation reason progression disease transition extension study ( Protocol number : JNJ-212082-JPN-203 ) separately plan . In addition , 5 mg prednisolone orally administer twice per day since Day 8 . On receive notification confirmation safety 500 mg drug , patient cohort 1 currently continuous administration receive increment 500 mg per day start next cycle ( If dose escalation would appropriate due safety reason , patient continue original dose ) . Furthermore , receive notification confirmation safety 1000 mg , patient previous cohort currently continuous administration receive increment 1000 mg per day well next cycle ( If dose escalation would appropriate due safety reason , patient continue original dose ) . JNJ-212082 orally administer per day . Comprising 28 day 1 cycle , administration continue discontinuation reason progression disease transition extension study . The drug administer least 1 hour prior meal 2 hour meal . The daily dose drug define 250 mg , 500 mg 1000 mg . In addition , 5 mg prednisolone ( market ) orally administer twice per day since Day 8 .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate , neuroendocrine differentiation small cell histology No Prior cytotoxic chemotherapy ( include estramustine ) treatment prostate cancer Surgically medically castrate , testosterone level &lt; 0.5 ng/mL PSA level least 2 ng/ml Screening PSA progression accord PCWG2 eligibility criterion objective progression RECIST criterion patient measurable disease androgen deprivation Surgery local prostatic intervention within 4 week first dose . In addition , clinically relevant sequela surgery resolve prior initial treatment Radiotherapy , immunotherapy within 4 week , single fraction palliative radiotherapy within 2 week administration prior initial treatment Known brain metastasis Uncontrolled hypertension ( systolic BP great 160 mmHg diastolic BP great 95 mmHg ) Active symptomatic viral hepatitis chronic liver disease</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Castration-resistant prostate cancer</keyword>
	<keyword>Abiraterone acetate</keyword>
	<keyword>JNJ-212082</keyword>
</DOC>